Holen Sie sich die Stockscreener-App
38.09
0.24%
0.09
Schlusskurs vom Vortag:
$38.00
Offen:
$37.94
24-Stunden-Volumen:
1.13M
Relative Volume:
0.38
Marktkapitalisierung:
$5.12B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-237.54M
KGV:
-15.22
EPS:
-2.5033
Netto-Cashflow:
$-145.05M
1W Leistung:
-7.05%
1M Leistung:
-10.00%
6M Leistung:
+114.47%
1J Leistung:
+0.00%
1-Tages-Spanne:
$37.38
$38.54
1-Wochen-Bereich:
$37.32
$41.34
52-Wochen-Spanne:
$14.62
$49.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Firmenname
Definium Therapeutics Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
38.09 | 6.10B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | Stifel | Buy |
| 2026-04-10 | Eingeleitet | Piper Sandler | Overweight |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-08-04 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
DRIEHAUS CAPITAL MANAGEMENT LLC Expands Definium Therapeutics In - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Traders Purchase High Volume of Definium Therapeutics Call Options (NASDAQ:DFTX) - MarketBeat
Definium Therapeutics (DFTX) Could Be 22% Undervalued On Positive Phase 3 Voyage Results - Sahm
Total non-current assets of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Definium Therapeutics Posts Strong Phase 3 GAD Data for DT120 - TipRanks
Definium Therapeutics (NASDAQ:DFTX) Coverage Initiated by Analysts at Bank of America - MarketBeat
Definium Therapeutics (DFTX) Is Down 5.6% After Positive Phase 3 GAD Data For DT120 ODT - Sahm
DFTX Initiates Coverage On B of A Securities -- Rating Set to Bu - GuruFocus
Definium Therapeutics Announces New Employee Inducement GrantsAugust 17, 2026 - BioSpace
BofA initiates Definium Therapeutics stock with buy on psychedelic drug potential - Investing.com Nigeria
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics (DFTX) Reports Positive Phase 3 GAD Trial Results Amid High Valuation - GuruFocus
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
DFTX Maintained by Maxim Group -- Price Target Raised to $55 - GuruFocus
Definium Therapeutics Price Target Raised to $55.00/Share From $50.00 by Maxim Group - Moomoo
Definium Therapeutics (DFTX): Commodore Capital discloses 2.41M-share, 1.8% beneficial stake - Stock Titan
Definium Therapeutics' Voyage Trial Success Reshapes Valuation Debate for Anxiety Drug - finance.biggo.com
DFTX News Today | Why did Definium Therapeutics stock go down today? - MarketBeat
Driehaus Capital trims percentage stake in Definium Therapeutics (DFTX) to 5.36% - Stock Titan
Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In Focus - Yahoo Finance
Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says - Moomoo
Is Successful Voyage Phase 3 Data Transforming the Investment Case For Definium Therapeutics (DFTX)? - Yahoo Finance
DFTX Maintained by Jones Trading -- Price Target Raised to $90.0 - GuruFocus
Definium says LSD-based pill reduces anxiety in late-stage study - Reuters
Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $90.00 at JonesTrading - MarketBeat
DFTX Maintained by Canaccord Genuity -- Price Target Raised to $64 - GuruFocus
Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODT - Yahoo Finance
DFTX Maintained by RBC Capital -- Price Target Raised to $66.00 - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock - MarketBeat
DFTX Maintained by Wells Fargo -- Price Target Raised to $72 - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $72.00 at Wells Fargo & Company - MarketBeat
JonesTrading Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $90 - Moomoo
Definium Phase III success with DT120 in anxiety - The Pharma Letter
Robert W. Baird Increases Definium Therapeutics (NASDAQ:DFTX) Price Target to $75.00 - MarketBeat
Canaccord raises Definium Therapeutics price target on trial data By Investing.com - Investing.com Nigeria
Canaccord raises Definium Therapeutics price target on trial data - Investing.com
DFTX Maintained by Baird -- Price Target Raised to $75.00 - GuruFocus
RBC Adjusts PT on Definium Therapeutics to $66 From $57, Keeps Outperform Speculative Risk Rating - marketscreener.com
Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study - MarketBeat
Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst - Seeking Alpha
DFTX Maintained by Needham -- Price Target Raised to $66.00 - GuruFocus
Needham & Company LLC Raises Definium Therapeutics (NASDAQ:DFTX) Price Target to $66.00 - MarketBeat
DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’ - TradingView
Finanzdaten der Definium Therapeutics Inc-Aktie (DFTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):